There are four FDA‐approved antibodies against VEGF: pegaptanib (OSI Pharmaceuticals, Long Island, NY, USA), ranibizumab (Genentech Inc., San Francisco, CA, USA), aflibercept (Regeneron, Tarrytown, NJ, USA), and brolucizumab (Novartis, Basel, Switzerland).[73] The frequent (typically monthly) treatment schedule revealed a significant unmet need in wet AMD management due to its surgical invasiveness.[74] In January 2022, the FDA approved faricimab (brand name Vabysmo) a ground‐breaking bispecific monoclonal antibody. The gene discussed is VEGFA; the disease is wet macular degeneration.